

Optibrium Expands US and UK Operations

- *Appoints Dr. Scott Lyon as Director of Business Development located on West Coast, USA*
 - *Moves to larger Headquarters in Cambridge, UK*

CAMBRIDGE, UK, 30 January 2018 – Optibrium, a developer of software for small molecule drug discovery, today announced it has appointed Dr. Scott Lyon as Director of Business Development and relocated its Headquarters and R&D facilities, to Cambridge Innovation Park, Cambridge, UK.

Optibrium's move to larger premises is driven by the company's rapid recent growth and will accommodate future expansion plans as it accelerates its R&D pipeline and extends research into new technologies to improve the efficiency and productivity of the drug discovery process. In the last year Optibrium has grown by 60%, expanding its computational chemistry, software development and application science teams.

As part of this growth strategy, Dr. Scott Lyon joins Optibrium on the west coast of North America, where he has responsibility for supporting the company's existing client base and for developing new business opportunities for StarDrop and the company's range of products for small molecule design, optimisation and data analysis. Scott brings 20 years of experience in business development and support for scientific software and services, having previously worked at organisations including MDL, CambridgeSoft and Thomson Reuters. He has BSc from Carnegie Mellon University and a PhD in Chemistry from the University of Arizona.

Dr Matthew Segall, Optibrium's CEO, commented: "As we move to larger, custom-designed offices, it is encouraging to see that our ongoing investment in the best scientists and engineers, who deliver cutting-edge features to our users, has resulted in strong revenue growth and thus sets the foundations for further expansion.

"We are pleased to welcome Scott to the US team and look forward to him developing our west coast community, building on our success by providing local support to our clients and maintaining Optibrium's reputation for excellence in customer service."

Dr Scott Lyon added: "Optibrium's unique drug discovery software and dedication to its clients offers a great opportunity to build for success. I am delighted to join the team and contribute to the company's further development."

For further information on Optibrium and StarDrop, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

ENDS

Notes to Editors:



Dr Scott Lyon, Director of Business Development, Optibrium

For high resolution image please email sarah.jeffery@zymecommunications.com

Media contact

Sarah Jeffery

Zyme Communications

E-mail: sarah.jeffery@zymecommunications.com

Phone: +44 (0) 7771 730919

Optibrium

Nick Foster

Head of Commercial Operations

E-mail: nick.foster@optibrium.com

Phone: +44 (0) 1223 815900

About Optibrium Ltd.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. The company's lead product, StarDrop, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process.

Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston, US. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

For further information visit www.optibrium.com or join in discussions on improving the productivity of drug discovery at www.optibrium.com/community.